Literature DB >> 15929767

Genetic influences in irritable bowel syndrome: a twin study.

Imtiyaz Mohammed1, Lynn F Cherkas, Stuart A Riley, Tim D Spector, Nigel J Trudgill.   

Abstract

BACKGROUND: Aggregation of symptoms of abdominal pain or bowel disturbance has been described in the families of patients with irritable bowel syndrome (IBS). This may be due to environmental factors, including learned responses to abdominal symptoms or a genetic contribution to the etiology of IBS.
OBJECTIVES: To determine the relative contribution of genetic factors to IBS by evaluating IBS symptoms in monozygotic (MZ) and dizygotic (DZ) twins.
METHODS: A total of 4,480 unselected twin pairs identified from a national volunteer twin register were asked to complete a validated questionnaire. IBS was defined by the Rome II criteria.
RESULTS: A total of 5,032 subjects replied (56% response rate). One thousand eight hundred seventy complete twin pairs were evaluable; 888 MZ pairs (82 male pairs, mean age 51, SD 13 (range 19-81) yr) and 982 DZ pairs (69 male pairs, age 52, SD 13 (20-82) yr). The prevalence of IBS was 17% in MZ and 16% in DZ twins. There was no significant difference in casewise concordance rates between the MZ and DZ twins (28%vs 27%, p=NS). Logistic regression analysis revealed that decreasing age and increasing psychosomatic score were independently associated with IBS. Multifactorial liability threshold modeling suggested that a combination of unique and shared environmental factors provided the best model for IBS. In contrast, somatization was shown to be moderately heritable.
CONCLUSION: Genetic factors are of little or no influence on IBS where the predominant influences appear to be environmental.

Entities:  

Mesh:

Year:  2005        PMID: 15929767     DOI: 10.1111/j.1572-0241.2005.41700.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  37 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.

Authors:  Michael Camilleri; David A Katzka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

2.  Familial aggregation of irritable bowel syndrome: a family case-control study.

Authors:  Yuri A Saito; Gloria M Petersen; Joseph J Larson; Elizabeth J Atkinson; Brooke L Fridley; Mariza de Andrade; G Richard Locke; Janice M Zimmerman; Ann E Almazar-Elder; Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2010-03-16       Impact factor: 10.864

Review 3.  IBS: An epigenetic perspective.

Authors:  Timothy G Dinan; John Cryan; Fergus Shanahan; P W Napoleon Keeling; Eamonn M M Quigley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-29       Impact factor: 46.802

4.  Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.

Authors:  Gareth J Sanger; Lin Chang; Chas Bountra; Lesley A Houghton
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

Review 5.  Genes and environment in irritable bowel syndrome: one step forward.

Authors:  N J Talley
Journal:  Gut       Date:  2006-12       Impact factor: 23.059

Review 6.  The psyche and the gut.

Authors:  Paul Enck; Ute Martens; Sibylle Klosterhalfen
Journal:  World J Gastroenterol       Date:  2007-07-07       Impact factor: 5.742

Review 7.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

Review 8.  Epigenetics and the developmental origins of inflammatory bowel diseases.

Authors:  Richard Kellermayer
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

9.  Irritable bowel syndrome: diagnosis and pathogenesis.

Authors:  Magdy El-Salhy
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

10.  Genetic variation in neuroendocrine genes associates with somatic symptoms in the general population: results from the EPIFUND study.

Authors:  Kate L Holliday; Gary J Macfarlane; Barbara I Nicholl; Francis Creed; Wendy Thomson; John McBeth
Journal:  J Psychosom Res       Date:  2010-05       Impact factor: 3.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.